Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
25.65
+0.94 (3.80%)
May 13, 2026, 11:55 AM EDT - Market open
Greenwich LifeSciences Market Cap
Greenwich LifeSciences has a market cap or net worth of $355.37 million as of May 13, 2026. Its market cap has increased by 168.26% in one year.
Market Cap
355.37M
Enterprise Value
368.88M
1-Year Change
168.26%
Ranking
Category
Stock Price
$25.65
Market Cap Chart
Since the IPO on September 25, 2020, Greenwich LifeSciences's market cap has increased from $68.69M to $355.37M, an increase of 417.37%. That is a compound annual growth rate of 33.92%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 11, 2026 | 334.31M | 14.85% |
| Dec 31, 2025 | 291.08M | 97.19% |
| Dec 31, 2024 | 147.61M | 9.21% |
| Dec 29, 2023 | 135.16M | -30.79% |
| Dec 30, 2022 | 195.29M | -38.84% |
| Dec 31, 2021 | 319.29M | -31.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Neumora Therapeutics | 348.02M |
| Surrozen | 344.72M |
| DiaMedica Therapeutics | 341.62M |
| C4 Therapeutics | 341.56M |
| Rezolute | 340.70M |
| Compass Therapeutics | 334.96M |
| Inhibikase Therapeutics | 331.53M |
| Immuneering | 330.60M |